0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Role of Renal Prostaglandin E 2 in Two-Kidney, One-Clip Renovascular Hypertension in Rabbits

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To investigate the role of renal prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) in renovascular hypertension, urinary PGE<sub>2</sub> was measured in rabbits with hypertension produced by left renal artery constriction. In the acute phase of renovascular hypetension (1 week after the constriction), urinary excretions of PGE<sub>2</sub> and sodium were significantly increased without correlations with changes in the systemic blood pressure (ΔBP). In this phase, ΔBP was directly proportional to plasma renin activity and plasma aldosterone concentration (p < 0.001). In the intermediate phase (5 weeks), ΔBP lost significant correlations with plasma renin activity and plasma aldosterone concentration and had a inverse correlation with urinary sodium excretion (p < 0.01). In the maintenance phase (10 weeks), ΔBP showed inverse correlations (p < 0.01) with both PGE<sub>2</sub> and sodium excretions, although their excretions decreased to normal levels. In the clipped kidney, only urinary PGE<sub>2</sub> excretion in the acute phase was significantly elevated (p < 0.02), and both sodium and PGE<sub>2</sub> excretions were significantly decreased (p < 0.01) in the maintenance phase. In the nonclipped kidney, urinary PGE<sub>2</sub> and sodium excretions were elevated in the acute and intermediate phases, but decreased to the control levels in the maintenance phase. In this phase, ΔBP showed inverse correlation (p < 0.01) with both PGE<sub>2</sub> and sodium excretions from the nonclipped kidney. The infusion of saralasin, an angiotensin II analogue, dose dependently reduced the blood pressure in the acute phase, but showed no effect in the intermediate and maintenance phases. The present data suggest that the renin-angiotensin system chiefly contributes to the development of hypertension in the acute phase. However, elevated renal PGE<sub>2</sub> may also partially act as a defensive factor by promoting urinary sodium excretion. In the maintenance phase, the reduced level of urinary sodium excretion in the nonclipped kidney, which has significant correlation with the reduced level of PGE<sub>2</sub>, may play an important role to maintain hypertension instead of the renin-angiotensin system.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1986
          1986
          05 December 2008
          : 44
          : 2
          : 142-149
          Affiliations
          Department of Urology, Kumamoto University Medical School, Kumamoto, Japan
          Article
          184219 Nephron 1986;44:142–149
          10.1159/000184219
          3534609
          © 1986 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8
          Categories
          Original Paper

          Comments

          Comment on this article